Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: a competing risk regression analysis.

Lee JY, Lee DH, Cho NH, Rha KH, Choi YD, Hong SJ, Yang SC, Cho KS.

Ann Surg Oncol. 2014 Feb;21(2):677-83. doi: 10.1245/s10434-013-3326-6. Epub 2013 Oct 22.

PMID:
24145996
2.

Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.

Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT)..

Eur Urol. 2013 Apr;63(4):693-701. doi: 10.1016/j.eururo.2012.08.054. Epub 2012 Sep 5.

PMID:
22959192
3.

Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.

Lee JY, Kang HW, Rha KH, Cho NH, Choi YD, Hong SJ, Cho KS.

J Cancer Res Clin Oncol. 2016 Apr;142(4):849-58. doi: 10.1007/s00432-015-2093-0. Epub 2015 Dec 12.

PMID:
26660495
4.

Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy.

Lee JY, Lee DH, Cho NH, Rha KH, Choi YD, Hong SJ, Yang SC, Cho KS.

Yonsei Med J. 2014 Mar;55(2):316-23. doi: 10.3349/ymj.2014.55.2.316.

5.

Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.

Moltzahn F, Karnes J, Gontero P, Kneitz B, Tombal B, Bader P, Briganti A, Montorsi F, Van Poppel H, Joniau S, Spahn M.

Prostate Cancer Prostatic Dis. 2015 Mar;18(1):31-7. doi: 10.1038/pcan.2014.41. Epub 2014 Dec 23.

PMID:
25535100
6.

Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification.

Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, di Muzio N, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A.

Eur Urol. 2013 Oct;64(4):557-64. doi: 10.1016/j.eururo.2013.03.006. Epub 2013 Mar 13.

PMID:
23506833
7.

Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.

Dell'Oglio P, Karnes RJ, Joniau S, Spahn M, Gontero P, Tosco L, Fossati N, Kneitz B, Chlosta P, Graefen M, Marchioro G, Bianchi M, Sanchez-Salas R, Karakiewicz PI, Poppel HV, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT)..

Urol Oncol. 2016 May;34(5):234.e13-9. doi: 10.1016/j.urolonc.2015.11.018. Epub 2015 Dec 17.

PMID:
26706120
8.

A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer.

Lee JY, Cho KS, Kwon JK, Jeh SU, Kang HW, Diaz RR, Ham WS, Koom WS, Keum KC, Choi YD.

Ann Surg Oncol. 2014 Nov;21(12):4026-33. doi: 10.1245/s10434-014-3780-9. Epub 2014 May 20.

PMID:
24841351
9.

Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses.

Koo KC, Cho JS, Bang WJ, Lee SH, Cho SY, Kim SI, Kim SJ, Rha KH, Hong SJ, Chung BH.

Cancer Res Treat. 2017 Mar 8. doi: 10.4143/crt.2017.004. [Epub ahead of print]

10.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
11.

Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.

Tilki D, Schlenker B, John M, Buchner A, Stanislaus P, Gratzke C, Karl A, Tan GY, Ergün S, Tewari AK, Stief CG, Seitz M, Reich O.

Urol Oncol. 2011 Sep-Oct;29(5):508-14. doi: 10.1016/j.urolonc.2009.07.003. Epub 2009 Oct 17.

PMID:
19837614
12.
13.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

14.

Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.

Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.

15.

Prediction of mortality after radical prostatectomy by Charlson comorbidity index.

Guzzo TJ, Dluzniewski P, Orosco R, Platz EA, Partin AW, Han M.

Urology. 2010 Sep;76(3):553-7. doi: 10.1016/j.urology.2010.02.069.

16.
17.

Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy.

Sivaraman A, Ordaz Jurado G, Cathelineau X, Barret E, Dell'Oglio P, Joniau S, Bianchi M, Briganti A, Spahn M, Bastian P, Chun J, Chlosta P, Gontero P, Graefen M, Jeffrey Karnes R, Marchioro G, Tombal B, Tosco L, van der Poel HH, Sanchez-Salas R.

World J Urol. 2016 Oct;34(10):1367-72. doi: 10.1007/s00345-016-1784-8. Epub 2016 Feb 20.

PMID:
26897499
18.

Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy.

Tollefson MK, Boorjian SA, Gettman MT, Rangel LJ, Bergstralh EJ, Karnes RJ.

Urol Oncol. 2013 Nov;31(8):1483-8. doi: 10.1016/j.urolonc.2012.03.014. Epub 2012 May 10.

PMID:
22578510
19.

Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.

Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, Kakoi N, Kawamura S, Tochigi T, Habuchi T, Ohyama C, Arai Y.

BJU Int. 2013 May;111(6):914-20. doi: 10.1111/j.1464-410X.2012.11658.x. Epub 2013 Jan 15.

20.

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV.

J Clin Oncol. 2005 Oct 1;23(28):6992-8.

PMID:
16192586

Supplemental Content

Support Center